Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Coloplast is a Danish medical device manufacturer specializing in intimate healthcare products across ostomy care (stoma bags/accessories), continence care (catheters/urological products), and wound & skin care. The company operates in 50+ countries with manufacturing concentrated in Denmark, Hungary, and China, serving aging demographics in developed markets. Strong recurring revenue model driven by chronic condition management and direct-to-consumer distribution channels.
Coloplast generates revenue through direct-to-patient subscription models and hospital/pharmacy distribution. High gross margins (65%+) reflect proprietary adhesive technologies, skin-friendly materials, and switching costs for chronic users. Pricing power stems from clinical differentiation (reduced leakage, skin complications) and reimbursement coverage in developed markets. Direct patient relationships via homecare services create recurring revenue streams with 80%+ retention rates. Geographic expansion focuses on aging populations in Europe (50% of sales), North America (25%), and emerging markets.
Organic revenue growth rates in core Ostomy and Continence segments (target: 5-7% annually)
Market share gains in US continence care against Hollister and ConvaTec
Pricing dynamics in European public healthcare tenders and reimbursement rate changes
Currency fluctuations (EUR/DKK vs USD, GBP, CNY) given 75% non-Danish revenue exposure
M&A activity in adjacent chronic care categories or geographic bolt-ons
Healthcare reimbursement pressure as European governments implement austerity measures and shift toward lowest-cost alternatives in public tenders, compressing pricing power
Regulatory pathway changes for medical devices under EU MDR requiring costly clinical evidence and potential product withdrawals
Demographic headwinds if colorectal cancer screening programs reduce ostomy surgery rates or minimally invasive techniques lower stoma creation
Market share erosion from ConvaTec and Hollister in ostomy care, particularly in US where direct-to-consumer models compete aggressively
Private label and low-cost Asian manufacturers gaining traction in price-sensitive emerging markets and European public tenders
Technology disruption from digital health monitoring, smart catheters, or bioengineered alternatives to traditional ostomy appliances
Elevated leverage (Debt/Equity 1.87x) limits M&A flexibility and creates refinancing risk if EBITDA declines or rates remain elevated
Pension obligations in Denmark exposed to discount rate changes and longevity assumptions
Currency translation losses given DKK reporting but diversified revenue base - USD/EUR volatility impacts reported earnings by 3-5% annually
low - Medical device demand for chronic conditions (ostomy, incontinence) is non-discretionary and driven by demographic trends rather than GDP. Procedure volumes remain stable through recessions as stoma surgeries follow colorectal cancer/IBD incidence and aging-related incontinence. However, elective wound care procedures and hospital capital equipment purchases show modest cyclicality.
Rising rates create moderate headwinds through higher debt servicing costs (Debt/Equity 1.87x) and valuation multiple compression for defensive healthcare stocks trading at premium P/E ratios. However, operating cash flow generation ($6.6B OCF on $14.7B market cap) limits refinancing risk. Currency impacts from rate differentials (DKK pegged to EUR) affect translation of USD/GBP revenues. Pension obligations in Denmark face discount rate sensitivity.
Minimal direct exposure - revenue comes from government reimbursement systems (60%+ in Europe) and private insurance rather than consumer credit. Hospital/distributor receivables carry low default risk. Tightening credit conditions could delay hospital capital purchases but don't affect consumable product demand.
value - Stock trades at 16.0x EV/EBITDA with 36% FCF yield following 39% one-year decline, attracting value investors seeking defensive healthcare exposure at discounted multiples. Historically attracted quality/dividend investors given stable cash flows and 2%+ dividend yields, but recent earnings decline (-28% net income growth) and margin pressure have shifted sentiment. Not a growth stock given mature markets and 3% organic growth rates.
moderate - Healthcare equipment stocks typically exhibit beta of 0.7-0.9 vs broader market. Recent 39% decline suggests elevated volatility driven by earnings disappointments and sector rotation away from defensive names. Currency exposure adds 5-10% earnings volatility. Lower volatility than biotech/pharma but higher than diversified healthcare conglomerates.